Teva Pharmaceutical Industries (NYSE:TEVA) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $17.84 and traded as high as $22.30. Teva Pharmaceutical Industries shares last traded at $21.30, with a volume of 8,123,668 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.88.

Teva Pharmaceutical Industries Stock Down 0.3 %

The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The firm has a market cap of $24.06 billion, a PE ratio of -24.99, a PEG ratio of 0.99 and a beta of 0.73. The company’s 50 day moving average price is $18.60 and its two-hundred day moving average price is $17.87.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently bought and sold shares of the business. UMB Bank n.a. lifted its stake in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co raised its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $50,000. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter worth $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in Teva Pharmaceutical Industries during the second quarter valued at $57,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.